| 1 |
34520436 | Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells. | 2022 Feb 1 |
6 |
| 2 |
33728771 | The ALK inhibitors, alectinib and ceritinib, induce ALK-independent and STAT3-dependent glioblastoma cell death. | 2021 Jun |
1 |
| 3 |
33758275 | Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines. | 2021 Mar 23 |
1 |
| 4 |
34176264 | Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK). | 2021 Jul 8 |
6 |
| 5 |
31972351 | Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer. | 2020 May |
1 |
| 6 |
31334113 | Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells. | 2019 |
1 |
| 7 |
30149189 | Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates. | 2018 Nov 30 |
1 |
| 8 |
28455243 | The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model. | 2017 Aug 1 |
4 |
| 9 |
29048652 | Activation of Src signaling mediates acquired resistance to ALK inhibition in lung cancer. | 2017 Nov |
3 |
| 10 |
26682573 | Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells. | 2016 Jan |
1 |
| 11 |
26849637 | Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells. | 2016 Mar |
1 |
| 12 |
25556163 | Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib. | 2015 Feb |
1 |
| 13 |
26019170 | Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer. | 2015 Sep 1 |
1 |